YILIMART - REAlease CD101-APC (REAL172) Kit, m

Clone REAL172 is an antibody fragment derived from the full CD101 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.

Clone REAL172 recognizes the mouse CD101 antigen, a type I transmembrane glycoprotein also known as Immunoglobulin superfamily member 2 (IgSF2) or V7. CD101 is expressed on monocytes, granulocytes, dendritic cells (DCs), and activated T cells. In humans CD101 inhibits the proliferative response of T cells to allogeneic cells or immobilized anti-CD3 antibody, suggesting that engagement of CD101 can antagonize TCR/CD3-mediated lymphocyte activation. Moreover, human peripheral CD8

⁺

T cells that express CD101 and CD103 display suppressive function after activation with intraepithelial cells or placental trophoblasts. In addition to its role on T cells, triggering CD101 on human cutaneous DC inhibits T cell proliferation via interleukin 10 (IL-10) production, suggesting that the CD101 molecule may be involved in tolerance induction. Studies in mice showed that cell surface expression of CD101 is highly correlated with functional suppressor activity within CD4

⁺

CD25

⁺

regulatory T cells both

in vitro

and

in vivo

.

The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Alternative names

EWI-101, Gm1016, Gm734, IGSF2

Technical specifications

Antigen: CD101
Clone: REAL172
Isotype control: REAL Control
Alternative names of antigen: EWI-101, Gm1016, Gm734, IGSF2
Distribution of antigen: monocytes, granulocytes, dendritic cells, T cells
Product format: Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
Storage: Store protected from light at 2–8 °C. Do not freeze.
Available conjugates: APC, PE

Figure 1

Splenocytes from C57BL6 mice were stained with REAlease CD101-APC (B) or with the corresponding REAL Control (A). REAlease CD101-APC was released using the REAlease Release Reagent (C). To show epitope accessibility after REAlease Complex release, the cells were washed with the REAlease Stop Reagent and restained with REAlease CD101-APC (D). Cells were labeled with Anti-Ly-6G antibodies in addition and analyzed by flow cytometry using the MACSQuant

^®

Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide (PI) fluorescence.

A:	B:

C:	D:

Figure 2

Splenocytes from C57BL6 mice were stained with REAlease CD101 Complexes or with the corresponding REAL Control (left images) as well as with Anti-Ly-6G antibodies and analyzed by flow cytometry using the MACSQuant

^®

Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide (PI) fluorescence.

Selected references
1. Penha-Gonçalves, C. et al. (2003) Identification of a structurally distinct CD101 molecule encoded in the 950-kb Idd10 region of NOD mice. Diabetes 52(6): 1551-1556
2. Fernandez, I. et al. (2007)
  
  CD101 surface expression discriminates potency among murine FoxP3
  ⁺
  regulatory T cells.
  
  J. Immunol. 179(5): 2808-2814
3. Mohammed, J. P. et al. (2011)
  
  Identification of CD101 as a susceptibility gene for
  Novosphingobium aromaticivorans
  -induced liver autoimmunity.
  
  J. Immunol. 187(1): 337-349

REAlease CD101-APC (REAL172) Kit, m

For research use only

您浏览过的商品

Alternative names

Technical specifications

Figure 1

Figure 2

Selected references

相关产品